IL17A and myeloid sarcoma: Also, serum levels of interleukin-12 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-13 (IL-13), interleukin-17 (IL-17), interleukin-21 (IL-21), interleukin-22 (IL-22), and interleukin-33 (IL-33) tend to be higher in MS patients in the active disease phase than in healthy controls and patients in remission, although interleukin-10 (IL-10) seems to help slow the disease’s progression.